Literature DB >> 14551897

Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.

Slavica Masina1, Michael M Gicheru, Stéphane O Demotz, Nicolas J Fasel.   

Abstract

Infection with Leishmania major parasites results in the development of cutaneous ulcerative lesions on the skin. We investigated the protective potential of a single, recombinant histone H1 antigen against cutaneous leishmaniasis in an outbred population of vervet monkeys, using Montanide adjuvant. Protection was assessed by challenging the animals with a mixture of vector sand fly salivary-gland lysate and a low dose of in vitro-derived parasites, thus more closely mimicking natural infection induced by L. major. The course of infection in immunized monkeys was compared with that of animals that had healed from a primary infection and were immune. The monkeys immunized with recombinant histone H1 showed a reduced development of lesion size, compared with controls. Our study therefore illustrates the potential use of histone H1 as a vaccine candidate against cutaneous leishmaniasis in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551897     DOI: 10.1086/378677

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine.

Authors:  Narges Khabazzadeh Tehrani; Mehdi Mahdavi; Fatemeh Maleki; Somayeh Zarrati; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-09-20

2.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

4.  Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from Leishmania major and Phlebotomus papatasi against Cutaneous Leishmaniasis.

Authors:  Touraj Miandoabi; Fariborz Bahrami; Vahideh Moein Vaziri; Soheila Ajdary
Journal:  Rep Biochem Mol Biol       Date:  2018-10

5.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

6.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

7.  Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Marcia W Carneiro; Diego M Santos; Kiyoshi F Fukutani; Jorge Clarencio; Jose Carlos Miranda; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Manuel Soto; Camila I de Oliveira
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  A review of adjuvants for Leishmania vaccine candidates.

Authors:  Joshua M Mutiso; John C Macharia; Michael M Gicheru
Journal:  J Biomed Res       Date:  2010-01

9.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.